On October 6, SBP GROUP rose 3.15% in regular trading, extending its recent upward trend amid positive market sentiment.

The increase follows Citigroup maintaining a buy rating and setting a target price of HKD 10.80, driven by optimism around its strategic partnership with STADA for pembrolizumab biosimilar TQB3570. Under this agreement finalized in late September, SBP GROUP secured upfront payments and could receive up to €53 million in milestone payments plus double-digit profit sharing, with cumulative potential deal value reaching approximately $3.4 billion this year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)